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Background
Here we describe a novel class of monomeric tumor-
targeted immunocytokines that comprise a single IL-2 var-
iant (IL2v) with abolished CD25 binding that is fused to
the C-terminus of a tumor specific antibody with a hetero-
dimeric Fc devoid of FcgR and C1q binding. For tumor
targeting, human/humanized high affinity antibodies
against CEA (GA504) or FAP (GA501) were selected.
Materials & methods
CEA- and FAP-IL2v activity was tested on effector cells by
assessing the activation of P-STAT5, cell proliferation,
sensitivity to Fas-induced apoptosis, expression of activa-
tion markers and cytokine release upon treatment. Safety,
pharmacokinetics, pharmacodynamics and anti-tumor effi-
cacy were analyzed in fully immunocompetent (CEA
transgenic) C57Bl/6 mice as single agent and in combina-
tion with ADCC competent antibodies in SCID/hCD16 tg
mice as well as Balb/neuT genetically engineered mice.
Tumor targeting was investigated in the orthotopic syn-
geneic Renca RCC model in Balb/c mice.
Results
FAP- and CEA-IL2v completely lack binding to CD25, but
retain IL-Rbg binding, and show pM binding affinity to
respective antigens, FAP or CEA. As a consequence of
abolished binding to CD25 they do not preferentially acti-
vate Tregs, but IL-2Rbg mediated activity is retained and
FAP- and CEA-IL2v activate NK, CD4+ and CD8+ T cells
as shown by induction of activation markers, cell prolifera-
tion and cytokine release. Furthermore, CEA-IL2v and
FAP-IL2v enhance the cytotoxic activity of NK cells when
combined with ADCC-competent antibodies. Mechanism
of action studies in fully immunocompetent mice showed
that the molecules strongly expand and activate NK, CD8+
T cells and gd T cells (up to 100-fold) and skew the CD4:
CD8 ratio strongly towards CD8+ T cells in the peripheral
blood, lymphoid tissues, and in the tumor. In C57Bl/6
mice. MicroSPECT/CT imaging with radioactively labeled
FAP-IL2v reveal good FAP-mediated tumor targeting in
the orthotopic syngeneic Renca model with low normal
tissue uptake and low accumulation in lymphoid tissues,
contrary to analogous IL-2 based immunocytokine that
shows preferential targeting to lymphoid tissue. Studies in
tumor-bearing mice show dose-dependent anti-tumor effi-
cacy of CEA-IL2v in syngeneic MC38-CEA and PancO2-
CEA models. Combination of a tumor-stroma targeted
TNCA-IL2v with an ADCC-competent ratHER2 antibody
in the Balb/neuT spontaneous breast cancer model results
in enhanced antitumoral efficacy.
Conclusion
Compared to classical IL-2-based immunocytokines, CEA-
and FAP-IL2v demonstrate superior safety, PK and tumor
targeting due to abolished CD25 binding, monovalency
and high-affinity to tumor antigens while failing to prefer-
entially induce Tregs. CEA- and FAP-IL2v retain the capa-
city to activate and expand NK and CD8+ effector T cells
both in the periphery and tumor microenvironment sup-
porting their further nonclinical and clinical investigation
for immunotherapy of cancer. Clinical trials with CEA-
IL2v are foreseen in 2014.
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